ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Carolyn Jean Presley, MD, and James L. Mulshine, MD, on New Lung Cancer CT Screening Guidelines and Treatment Burden

James L. Mulshine, MD, of Rush University Medical Center, and Carolyn Jean Presley, MD, of Yale Cancer Center/Yale School of Medicine, discuss the burden on patients and the Medicare system as new lung cancer CT guidelines are put into effect and treatment of early-stage NSCLC increases (Abstract 7533).

Colorectal Cancer

Chloe Evelyn Atreya, MD, PhD, and Axel Grothey, MD

Chloe Evelyn Atreya, MD, PhD, and Axel Grothey, MD, on Efficacy of Targeted Treatments in BRAF-Mutated Metastatic Colorectal Cancer

Chloe Evelyn Atreya, MD, PhD, of the University of California, San Francisco, talks with Axel Grothey, MD, of the Mayo Clinic, about new data on trametinib, dabrafenib, and panitumumab in patients with the BRAF V600E mutation and vemurafenib plus irinotecan and cetuximab in BRAF-mutated metastatic colorectal cancer (Abstracts 103 and 3511).

Cost of Care

Leonard Saltz, MD

Leonard Saltz, MD, on Issues of Value in Melanoma Treatment

Leonard Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses how the cost of care affects behavior and decision-making on the part of patients and oncologists.

Breast Cancer

Andrew D. Seidman, MD, and Clifford A. Hudis, MD

Andrew D. Seidman, MD, and Clifford A. Hudis, MD, on Breast Cancer Decision Analysis

Clifford A. Hudis, MD, and Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, discuss the use of the decision support system Watson for Oncology and results of the iCanCare study on second opinions (Abstracts 566 and 6508).

Prostate Cancer

Howard M. Sandler, MD

Howard M. Sandler, MD, Summarizes Results of the RTOG 0521 Trial on Localized, High-Risk Prostate Cancer

Howard M. Sandler, MD, of Cedars-Sinai Medical Center discusses the improvement of overall survival with the use of adjuvant chemotherapy following androgen suppression and radiotherapy (Abstract LBA5002).

Feb

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Carolyn Jean Presley, MD, and James L. Mulshine, MD, on New Lung Cancer CT Screening Guidelines and Treatment Burden

Chloe Evelyn Atreya, MD, PhD, and Axel Grothey, MD, on Efficacy of Targeted Treatments in BRAF-Mutated Metastatic Colorectal Cancer

Leonard Saltz, MD, on Issues of Value in Melanoma Treatment

Andrew D. Seidman, MD, and Clifford A. Hudis, MD, on Breast Cancer Decision Analysis

Howard M. Sandler, MD, Summarizes Results of the RTOG 0521 Trial on Localized, High-Risk Prostate Cancer

‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?

Medical Societies and More Respond to HHS RFI on AI Use in Clinical Care

Perioperative Enfortumab Vedotin Plus Pembrolizumab May Reduce Risk of Recurrence in Patients With Muscle-Invasive Bladder Cancer

SABCS 2025: Top Picks From a Breast Cancer Specialist

Intravesical Immunotherapy Shows Recurrence Control in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer